Vesalio Appoints Daniel Davis to Its Board of Directors and as Advisor to the CEO
Daniel Davis is appointed to Vesalio’s Board of Directors and as Advisor to the CEO
NATURE Randomized Controlled Trial Meets Primary Endpoint Evaluating enVast-Assisted Mechanical Thrombectomy in Large-Thrombus STEMI
Results showed a reduction in infarct size compared with conventional PCI in STEMI patients with large thrombus burden. Results were presented as Late-Breaking Science at ESC Congress 2026.
Vesalio Announces FDA 510(k) Clearance of pVasc NET, a Next-Generation Peripheral Mechanical Thrombectomy Device with Integrated Distal Filter
New device expands Vesalio’s pVasc platform with integrated clot-capture technology designed to retain clot fragments during retrieval
Vesalio Announces Late-Breaking Clinical Trial Presentation of the enVast NATURE Study at the ESC Congress 2026
NATURE trial, a prospective randomized controlled trial comparing the safety and effectiveness of thrombectomy using enVast before conventional PCI versus standard of care alone, was selected for the prestigious Late-Breaking Clinical Trials session at the European Society of Cardiology Congress.
Vesalio Appoints Greg Cook as Chief Commercial Officer
Greg Cook joins Vesalio as Chief Commercial Officer to lead commercial strategy and execution across its thrombectomy platform.
Vesalio Expands International Neurovascular Portfolio with CE Mark of NeVa VS and NeVa 3.0 mm and Receives Additional FDA 510(k) Clearance for its Aspiration Catheters
Company advances global neuro-intervention footprint with new CE-marked devices for vasospasm and stroke, and expanded U.S. indications for aspiration catheters.
Vesalio Receives FDA 510(k) Clearance of enVast, the First Stent-Based Coronary Thrombectomy Technology
The FDA clearance of enVast redefines coronary thrombectomy treatment and further expands Vesalio’s commercial platform.
Vesalio Receives Two FDA 510(k) Clearances, Advancing Its Comprehensive Thrombectomy Platform with Aspiration Technology
The FDA clearances expand Vesalio’s thrombectomy portfolio to support its growth strategy in the rapidly expanding multi-billion-dollar global thrombectomy market.
Vesalio Announces Launch of pVasc Study in the U.S. While Featuring the pVasc Thrombectomy System at VIVA, VEITH, and TCT
Vesalio Introduces pVasc™ U.S. Clinical Study to capture real-world data and optimize results for patients suffering from peripheral vascular disease.
Vesalio launches pVasc Thrombectomy System in the U.S. for peripheral occlusions
Introducing pVasc™ mechanical thrombectomy system for the safe and effective non-surgical removal of occlusions from the peripheral vasculature
